drugset
drugset / Trial / NCT01577758

Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

NCT01577758 ↗

Phase 1 Completed 41 enrolled Millennium Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an Open-Label, Multicenter, Dose Escalation, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C.

Timeline

Start
2012-06
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject INDUSATUMAB VEDOTIN Unknown 0.3 mg/kg Other

Indications

digestive system cancer